Talking About Tumors with Ryann and Ryan

An introductory podcast for trainees interested in medical oncology to prepare for clinic and the boards.

Hosted by oncologists @ryangholstead and @ryann762

[Arndt Vogel @ArndtVogel]

Safety and efficacy of zoldonrasibplus daraxonrasib in patients with 2L+ KRAS G12D metastatic mPDAC
@ ESMO-Gi
😍>90% DCR in 2nd/3rd line therapy
👉tox driven by daraxonrasib, only 5% treatment discontionuation
👉amazing..
@myESMO @ASCO

[Talking About Tumors with Ryann and Ryan @TalkingTumors]

A small talk on a big new drug for pancreas adenocarcinoma:
"Daroxonrasib: A KRAS(on) inhibitor (mini-discussion)" at https://t.co/M68gEZSibe

[Ryan Holstead @ryangholstead]

1/ Impressive #challenge clinical trial update at #asco26 making a financial case (from Canadian perspective)

Bottom line - SEP can improve DFS for St iii CRC and despite an upfront cost, would save health systems money overall

[Ryan Holstead @ryangholstead]

1/ A novel KRAS(on) inhibitor improves survival in previously treated patients with metastatic pancreatic cancer with a RAS G12 mutation

mOS 13.2v6.6 months (HR 0.4)
Toxicities: rash (85%, Gr3 13%)
Limitations: Ctrl arm drop out (>10%), small population of non G12

[Talking About Tumors with Ryann and Ryan @TalkingTumors]

@oncology_bg @JCOOP_ASCO This is great and easy to read Bishal, will be sure to circulate to our trainees. Thank you!

[Talking About Tumors with Ryann and Ryan @TalkingTumors]

Another ASCO, another great discussion around some of the key trials' strengths and weaknesses by @oncology_bg .

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

My @ecancer #ASCO25 highlights video is out. I recorded it Sunday morning, so I’ll discuss some newer trials on a different video.

https://t.co/wIXLeJ0VdG

[Dr. Nina Niu Sanford @NiuSanford]

Come on #ASCO25, this 💯 should have been a plenary!

7% improvement in 8-yr OS w exercise in adjuvant colon ca, greater than benefit for adding oxali to 5-FU (5% at 10 yrs in MOSAIC).

Exercise = $ effective, ~0 tox, & gives pts sense of empowerment.

Congrats Chris Booth et al!

[Talking About Tumors with Ryann and Ryan @TalkingTumors]

Carcinoids? NETs? NECs? PRRT? DOTATATE? oh my! An introduction to Neroendocrine tumors:

https://t.co/t9l0satTpe

[Talking About Tumors with Ryann and Ryan @TalkingTumors]

We have reviewed on the study methods and early data on iDFS. The authors present some hypotheses on CDK 4/6resistance mechanisms that would be meaningful to test in a trial setting.

https://t.co/nBau9crkIN

[Talking About Tumors with Ryann and Ryan @TalkingTumors]

Does adjuvant use of CDK 4/6 inhibitors help patients live longer or live better? A negative argument -
https://t.co/MvxTDL3bEj

[Talking About Tumors with Ryann and Ryan @TalkingTumors]

We will be back very soon with a discussion on neuroendocrine tumors, and glioblastoma multiforme.

We will then move to some interviews with allied subspecialists.

Please let us know if we omitted any major tumor sites that you would want to hear about!

[NonsparseOncologist @5_utr]

😬 Another article attempting to argue HRs are too challenging to interpret and we should replace with RMST 😬

https://t.co/FjLl1Rouub

[Talking About Tumors with Ryann and Ryan @TalkingTumors]

Our discussion on Hepatocellular carcinoma is now live! Let us know what you think and we'll be back asap to review Glioblastoma multiforme

https://t.co/iIHa4vE2Di

[Talking About Tumors with Ryann and Ryan @TalkingTumors]

We hope this was a helpful summary and look forward to publishing our discussion on the current standards of care for advanced HCC soon!

[Talking About Tumors with Ryann and Ryan @TalkingTumors]

Putting final touches on our discussion on Hepatocellular Carcinoma (HCC). This is a fascinating tumor with significant global impact and a great need for better treatment options, especially in the setting of NAFLD/M(N)ASH cirrhosis.... /

[Talking About Tumors with Ryann and Ryan @TalkingTumors]

Differences in pathogenesis in viral and non-viral HCC may provide rationale for differences in sensitivity to ICI. Giving the growing rates of non-viral HCC, we hope to see trials in the future better isolating outcomes by each subgroup. /
https://t.co/yJwloIMOJb